Barr’s generic Allegra
This article was originally published in The Tan Sheet
Executive Summary
Barr Labs has received final FDA approval for its generic version of Aventis' Allegra (fexofenadine HCl) 60 mg capsules, the Woodcliff Lake, N.J.-based firm announced July 14. The company is the first to file an ANDA that has a paragraph IV patent challenge on the Allegra capsule patents and will have 180 days of marketing exclusivity on the product, Barr states. Aventis tried to prevent approval of the ANDA until various Allegra patents expired, but a New Jersey federal court ruled in June 2004 that Barr did not infringe on three Allegra composition patents (1"The Tan Sheet" July 5, 2004, In Brief). Barr still has five patent-related issues pending in litigation with Aventis and anticipates the case will go to court in early 2006...
You may also be interested in...
Allegra patents
Five generic companies do not infringe two composition patents for Allegra (fexofenadine), a Newark, N.J. federal court ruled June 29. The ruling granted Barr, Impax, Teva, Mylan and Dr. Reddy's summary judgment of noninfringement on two patents. Barr also received summary judgment of noninfringement on a third composition patent for Allegra, while Barr, Mylan and Impax were denied summary judgment of noninfringement on an Allegra D composition patent. Barr said a total of seven patents remain at issue in its litigation with Aventis and expects the case to go to trial in mid-2005...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.